Retatrutide

Retatrutide is a peptide investigated for its activity at three receptors involved in metabolic signaling. Research interests include obesity and type 2 diabetes, while possible effects on cardiovascular risk remain an area requiring careful evaluation.

Glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon participate in the regulation of nutrient handling and energy balance. Their receptor pathways have distinct but interacting roles in glucose metabolism and physiological responses to food.

Retatrutide is studied as an agonist of the GLP-1, GIP, and glucagon receptors. This combined receptor activity is being investigated for effects on appetite, blood glucose regulation, and energy metabolism, rather than as evidence that all proposed clinical benefits are established.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 03 · Early human research

Small or early-stage human studies exist, with limited certainty and reproducibility.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents retatrutide as a compound intended to engage several metabolic pathways simultaneously. It associates this approach with potential reductions in body weight, improved blood glucose regulation, and favorable cardiovascular effects, but the supplied excerpts do not provide supporting study details. The guide also characterizes tolerability favorably while identifying gastrointestinal symptoms and possible pancreatic or gallbladder concerns.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The excerpts do not establish the magnitude, durability, or comparative value of the proposed effects, particularly for cardiovascular outcomes. Without primary research references, retatrutide-specific findings cannot consistently be separated from assumptions based on related compounds.

Safety data are limited, and the guide's favorable tolerability characterization should not be interpreted as an established safety conclusion. The source mentions nausea, loose stools, abdominal fullness, fatigue, and dizziness, and raises concerns about pancreatic inflammation and gallbladder disorders, including in people with relevant pre-existing conditions. This summary is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Retatrutide dual receptor agonist obesity diabetes”
• “Retatrutide clinical trial diabetes management”
• “Tirzepatide and R etatrutide comparison in metabolic”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN